September 29, 2016

OICR funding new network to enhance molecular pathology research in Ontario

omprn-announce

Today OICR announced the launch of the Ontario Molecular Pathology Research Network (OMPRN), which will be based at Queen’s University and will bring together pathologists across the province.

Pathology is key to the early detection, diagnosis and treatment of cancer. An accurate diagnosis can provide better prognostic information and allow doctors to better target therapies. Pathology research can also lead to the development of new treatments that target specific cancer-driving mutations, genes and pathways, reducing the need for treatments with unwanted side effects.

Continue reading – OICR funding new network to enhance molecular pathology research in Ontario

June 28, 2016

OICR’s Dr. Clare Jeon discusses how the discovery of protein signatures could lead to cheaper, easier diagnostic tests for prostate cancer

Dr. Clare JeonResearchers at the Ontario Institute for Cancer Research, University Health Network and Eastern Virginia Medical School, in a paper published today in the journal Nature Communications, have identified protein signatures in urine that can accurately diagnose aggressive prostate cancer. The signatures could be used to develop a test for prostate cancer that uses a patient’s urine sample to determine whether he has prostate cancer and another test that could identify how aggressive the disease is. This would help to replace more invasive tests such as PSA test and biopsy, which also have high rates of over-diagnosis and in many cases lead to over-treatment.

Continue reading – OICR’s Dr. Clare Jeon discusses how the discovery of protein signatures could lead to cheaper, easier diagnostic tests for prostate cancer